Dividends Inside 
Novo Nordisk A/S Sponsored ADR
NVO
$37.65 (- $0.61 - 1.59%)
Last updated: 2026-10-08 16:24 UTC
Novo Nordisk A/S Sponsored ADR trades under ticker NVO on NYSE as a stock. Use this page to review stock price, share price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US6701002056, CUSIP 670100205. Also searched as Novo Nordisk A/S Sponsored.
Related researchNVO stock priceNVO share priceNVO dividend historyNVO dividend yieldNovo Nordisk A/S Sponsored dividend historyNovo Nordisk A/S Sponsored dividend yield670100205Novo Nordisk A/S Sponsored stockNovo Nordisk A/S Sponsored share price
About the Company
Novo Nordisk A/S Sponsored ADR is a healthcare company focused on discovering, developing, manufacturing, and marketing pharmaceutical products. The company’s current business is organized around diabetes and obesity care, where it offers treatments and related devices for chronic metabolic conditions, and rare disease, where it serves patients with specialized therapies for blood disorders and endocrine disorders. Novo Nordisk A/S Sponsored ADR works with patients, healthcare professionals, and care providers across global markets, supplying medicines used in long-term disease management. As a sponsored ADR, it gives investors a U.S.-traded representation of the company’s underlying shares while reflecting the performance of its international healthcare operations. The company is headquartered in Bagsværd, Denmark, and remains a major participant in the global pharmaceutical industry through its focus on chronic disease treatment and specialty care.
Price History
Latest News for NVO
Novo Nordisk, United Laboratories' Obesity Drug Shows Body Weight Reduction in Chinese Patients in Phase 2 Study
Novo Nordisk (NVO) and United Laboratories International said Wednesday their therapeutic candidate
Novo Nordisk A/S: Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial in Chinese patients with type 2 diabetes
UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo NordiskIn a phase 2 trial in Chinese people with type 2 diabetes, UBT251 showed a mean HbA1c reduction of up to 2.16%, and a mean body weight reduction of up to 9.8% after 24 weeks, showing improvements relative to placebo and semaglutide 1 mgThe safety and tolerability profile of UBT251 appeared consistent with what has been observed in other clinical tria
Hims & Hers Health (HIMS) Valuation After Novo Nordisk Weight Loss Deal And Product Exit
Executive moves and renewed weight loss partnership put Hims & Hers Health (HIMS) in focus Hims & Hers Health (HIMS) has been in the spotlight after renewing its partnership with Novo Nordisk to offer Novo’s weight loss drugs exclusively, while discontinuing its own competing products and limiting compounded versions. See our latest analysis for Hims & Hers Health. At a share price of $22.46, Hims & Hers has had a sharp 43.7% 1 month share price return but a 32.8% decline year to date. The 3...
Gilead to Buy Ouro Medicines for $2.2 Billion. Why the Deal Is Key to Future Stock Gains.
Gilead plans to develop Ouro’s lead drug candidate, gamgertamig, alongside a Belgian pharma company.
Jefferies trims Novo Nordisk target as GLP-1 pricing erosion and oral Wegovy launch uncertainty cloud first quarter
The broker retains its hold rating, warning that overall portfolio growth may stall even as the oral weight-loss pill gains traction Jefferies has trimmed its price target on Novo Nordisk (NYSE:NVO), the Danish pharmaceutical giant, to DKK270 from DKK275, maintaining a 'hold' rating ahead of...
LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity Drug
Lexicon Pharmaceuticals stock jumps as NVO launches phase I study of oral obesity candidate LX9851, advancing a promising partnered therapy.